HIV virologic response and baseline genotypic resistance in a long-acting cabotegravir/rilpivirine initiation program

AIDS. 2023 Aug 1;37(10):1641-1642. doi: 10.1097/QAD.0000000000003590.
No abstract available

Publication types

  • Letter

MeSH terms

  • Anti-HIV Agents* / therapeutic use
  • Anti-Retroviral Agents / therapeutic use
  • HIV Infections* / drug therapy
  • Humans
  • Pyridones / therapeutic use
  • Rilpivirine / therapeutic use

Substances

  • cabotegravir
  • Anti-Retroviral Agents
  • Rilpivirine
  • Pyridones
  • Anti-HIV Agents